Want to see HK:2607 full AI Analyst Report?
2607 Stock Chart & Stats
HK$11.44
-HK$0.10(-0.83%)
At close: 4:00 PM EDT
HK$11.44
-HK$0.10(-0.83%)
Day’s Range― - ―
52-Week RangeHK$10.96 - HK$12.66
Previous CloseN/A
Volume1.45M
Average Volume (3M)2.90M
Market Cap
HK$63.93B
Enterprise ValueHK$82.01K
Total Cash (Recent Filing)HK$45.98B
Total Debt (Recent Filing)HK$62.65B
Price to Earnings (P/E)10.4
Beta0.68
Next Earnings
Oct 23, 2026EPS Estimate
0.27Next Dividend Ex-DateN/A
Dividend Yield4.71%
Share Statistics
EPS (TTM)1.27
Shares Outstanding919,072,700
10 Day Avg. Volume2,690,085
30 Day Avg. Volume2,904,360
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)0.50
Price to Sales (P/S)0.13
P/FCF Ratio9.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.46
Revenue Forecast (FY)HK$300.05B
Bulls Say, Bears Say
Bulls Say
Revenue Re-accelerationThe sharp top-line re-acceleration indicates stronger demand, distribution volumes, or product contribution. If sustained, broader healthcare coverage and channel reach can support growth across both manufacturing and distribution.
Improved Cash GenerationMaterially stronger operating and free cash flow improves funding capacity for inventory, product development, capital investment, and shareholder returns. Cash conversion near 70% of net income also supports earnings quality.
Integrated Healthcare PlatformIntegration across manufacturing and distribution provides recurring access to hospitals, pharmacies, and healthcare providers. The model can improve product reach, customer stickiness, purchasing frequency, and control over commercialization.
Bears Say
Structurally Thin MarginsLow profitability leaves limited protection against procurement, logistics, labor, or pricing pressure. The decline in EBIT margin despite strong revenue growth suggests cost or product-mix challenges that could constrain durable earnings expansion.
Higher LeverageThe higher debt burden reduces financial flexibility and increases sensitivity to funding costs or weaker operating conditions. Although equity has grown and leverage remains manageable, the recent step-up warrants ongoing balance-sheet discipline.
Earnings And Working-Capital RiskLower earnings despite much stronger revenue points to pressure on profitability and earnings quality. The distribution model also requires substantial working capital, so inventory or receivables growth can weaken cash generation and raise funding needs.
Shanghai Pharmaceuticals Holding Co News
2607 FAQ
What was Shanghai Pharmaceuticals Holding Co Ltd Class H’s price range in the past 12 months?
Shanghai Pharmaceuticals Holding Co Ltd Class H lowest stock price was HK$10.96 and its highest was HK$12.66 in the past 12 months.
What is Shanghai Pharmaceuticals Holding Co Ltd Class H’s market cap?
Shanghai Pharmaceuticals Holding Co Ltd Class H’s market cap is HK$63.93B.
When is Shanghai Pharmaceuticals Holding Co Ltd Class H’s upcoming earnings report date?
Shanghai Pharmaceuticals Holding Co Ltd Class H’s upcoming earnings report date is Oct 23, 2026 which is in 56 days.
How were Shanghai Pharmaceuticals Holding Co Ltd Class H’s earnings last quarter?
Shanghai Pharmaceuticals Holding Co Ltd Class H released its earnings results on Aug 27, 2026. The company reported HK$0.77 earnings per share for the quarter, the consensus estimate of HK$0.77 by HK$0.
Is Shanghai Pharmaceuticals Holding Co Ltd Class H overvalued?
According to Wall Street analysts Shanghai Pharmaceuticals Holding Co Ltd Class H’s price is currently Overvalued.
Does Shanghai Pharmaceuticals Holding Co Ltd Class H pay dividends?
Shanghai Pharmaceuticals Holding Co Ltd Class H pays a Semiannually dividend of HK$0.405 which represents an annual dividend yield of 4.71%. See more information on Shanghai Pharmaceuticals Holding Co Ltd Class H dividends here
What is Shanghai Pharmaceuticals Holding Co Ltd Class H’s EPS estimate?
Shanghai Pharmaceuticals Holding Co Ltd Class H’s EPS estimate is 0.27.
How many shares outstanding does Shanghai Pharmaceuticals Holding Co Ltd Class H have?
Shanghai Pharmaceuticals Holding Co Ltd Class H has 919,072,700 shares outstanding.
What happened to Shanghai Pharmaceuticals Holding Co Ltd Class H’s price movement after its last earnings report?
Shanghai Pharmaceuticals Holding Co Ltd Class H reported an EPS of HK$0.77 in its last earnings report, expectations of HK$0.77. Following the earnings report the stock price went down -0.437%.
Which hedge fund is a major shareholder of Shanghai Pharmaceuticals Holding Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:2607
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Pharmaceuticals Holding Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.71%
12-Months-Change
Fundamentals
Return on Equity
4.71%
Trailing 12-Months
Asset Growth
9.39%
Trailing 12-Months
Company Description
Shanghai Pharmaceuticals Holding Co Ltd Class H
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company based in Shanghai, People's Republic of China, maintains a robust presence across the pharmaceutical and healthcare industries. Its core activities involve the research, development, production, distribution, and retail of medical and wellness products. The company is strategically divided into Production, Distribution, Retail, and Other segments. Its comprehensive product portfolio includes Western and traditional Chinese medicines, health supplements, and medical devices, addressing a broad spectrum of therapeutic areas such as oncology, cardiovascular health, central nervous system disorders, general infections, immunology, digestive and metabolic conditions, and respiratory ailments, totaling approximately 700 distinct drug varieties. Beyond manufacturing, Shanghai Pharmaceuticals offers extensive pharmaceutical supply chain solutions, encompassing warehousing, logistics, and value-added services for manufacturers, hospitals, distributors, and retail pharmacies. The company also boasts a significant retail footprint, operating a network of approximately 2,000 retail pharmacies across 24 provinces, alongside an active online drug business. Furthermore, it provides various specialized services, including consulting, asset management, clinical trials, medical aid programs, physician and patient education, e-prescription management, and remote/cloud-based hospital services. Established in 1994, Shanghai Pharmaceuticals Holding Co., Ltd. operates as a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.
Technical Analysis
China Health Group
―
Sinopharm Group Co
―
IVD Medical Holding Limited
―
Medlive Technology Co., Ltd.
―
Charmacy Pharmaceutical Co., Ltd. Class H
―